National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Fidaxomicin is indicated for the treatment of CDI also known as CDAD in adult patients.

Rapid Review

Commenced Completed Outcome
09/03/2012 23/03/2012 Full Pharmacoeconomic Evaluation Recommended.

Pharmacoeconomic Evaluation

Commenced Completed Outcome
05/12/2012 05/02/2013 Reimbursement recommended

Fidaxomicin (Dificlir®) may be considered a cost-effective use of resources. It should be prescribed according to the recommendations outlined in the recently updated National Clostridium difficile Guidelines (due to be completed in February 2013 www.hpsc.ie).

Fidaxomicin (Dificlir)